ERBB2 and adenocarcinoma: All ICERs exceeded the WTP threshold of $41,511 per QALY, indicating that CAD-CHM is not cost-effective compared with chemotherapy alone for HER2-negative advanced G/GEJ adenocarcinoma from the perspective of the Chinese healthcare system.